Three delivery models, one family calendar in Wentzville

In-person clinic, at-home telehealth, and clinic first then home, compared on what each asks of the caregiver who keeps the schedule.

Three delivery models, one family calendar. That is the real comparison facing a caregiver who has just heard that a supervised depression treatment might be an option for someone they love.

People form opinions about which model they want long before any prescription exists. Of the 443 Midwest adults in our June 2026 poll, 44 percent wanted this kind of therapy at a clinic in person. Home telehealth drew 22 percent, the begin-at-clinic, shift-home plan took 23, and 11 percent did not care either way. The final numbers describe a market that leans toward supervision.

Here is what each model asks of you, from the seat of the person doing the driving.

Model one: the in-person clinic

The FDA-approved option belongs here. Esketamine, sold as Spravato, is authorized for depression that earlier medicines did not lift, and every dose happens at a certified health care site with monitoring afterward; by regulation, no home version exists. Brain Recovery Centers lays out its Spravato treatment process for anyone curious how one clinic runs this model.

What it asks of you: a block of time longer than the appointment, repeated on the clinic's early schedule, plus the drive both ways. The patient cannot drive afterward, so you or someone else is the transportation plan. From Wentzville, travel time depends on whether the clinic sits this side of the Missouri River or across the metro, and on how I-70 behaves that morning.

What it gives you: trained staff in the room, a clinical eye on how the person responds, and a structure that does not depend on your household remembering anything.

What to ask: total visit length door to door, how often visits happen in month one, what the plan is if a session goes badly, and which insurers the practice contracts with.

Model two: at-home telehealth

These services prescribe generic ketamine, usually a lozenge or dissolving tablet, after a video visit. That is off-label use for mood, oversight varies widely between companies, and it is a different product and regulatory category from the clinic option, whatever words the marketing borrows.

What it asks of you: more vigilance, not less. The medication lives in your house, someone has to be present and alert during a dose, and you inherit the monitoring role clinic staff would otherwise hold, without their training.

What it gives you: no drive, no scheduling around office hours, and a lower barrier for someone whose anxiety makes leaving the house its own obstacle. The 22 percent of respondents who preferred it are a real constituency, not a rounding error.

What to ask: the prescriber's name and whether their license is valid in Missouri, what screening comes before the first prescription, who answers the phone during a session, how refills and storage are handled, and what the exit plan is if it does not help.

Model three: clinic first, home later

The hybrid edged pure telehealth, 23 percent to 22, which surprised us. It is what most people describe when they think it through out loud: supervision while the response is unknown, convenience once things settle.

What it asks of you: the heaviest logistics at the start, then a taper, plus acceptance of a handoff, and handoffs are where care gets dropped. If the starting clinic and the continuing service are different organizations, someone must own the link between them, and that someone is often the family.

What it gives you: an observed beginning with an end to the driving in sight, which is easier to commit to than an open-ended schedule. Ask who decides when the switch happens, on what criteria, whether records move automatically, and who is responsible during the gap.

The comparison in plain terms

• Regulatory status: the clinic route includes a medication whose FDA approval covers treatment-resistant depression; the home route is off-label prescribing; the hybrid depends on what each half involves.
• Your time cost: high and ongoing, low, or high then falling.
• Your supervision burden: low, high, or shifting from low to high.
• Coverage odds: usually strongest where an approved indication and an established billing path exist, though only your plan can say.
• Failure mode: a schedule the family cannot sustain, an unsupervised treatment in a house that needed supervision, or a handoff nobody owned.

Do not forget the option nobody has heard of

Transcranial magnetic stimulation is a non-drug depression treatment, and our survey found it almost unknown. Half the respondents, 51 percent, had never heard of TMS but wanted a drug-free option; 25 percent knew nothing of it and did not care. Of the minority who knew it, 13 percent put great weight on drug-free care and 12 percent said it changed little. Altogether, 64 percent cared about avoiding a drug, while only 25 percent knew such an option existed. If the person you care for balks at another medication, raise that gap with their doctor.

What decides it

In practice the deciding vote usually belongs to the clinical assessment and the insurance answer, not the family's preference. Among the people we surveyed, 85 percent listed coverage as a top-two consideration, far ahead of nearness at 43 percent, and preference bends around what a plan will pay.

So run the comparison after the appointment, not instead of it. In our results, their own physician's recommendation was the persuader for 74 percent, and it will also cut your three models to the one or two truly on the table.

What this article cannot do

It cannot tell you which model is right; that call rests on one person's history and belongs to someone qualified to make it. Nothing here is medical advice, no outcome is promised, and an available treatment is not necessarily an appropriate one. Bring the comparison to a clinician and let them say which column applies.

One last note, offered sincerely. Caring for someone whose depression has not responded to treatment is heavy, and the fear is real. If they talk about not wanting to be alive, or you are simply scared, call or text 988 at any hour, from anywhere in the country, to reach the Lifeline. You can call about them, or about you.

Methodology

This publisher paid for and commissioned the study. Pollfish collected 443 completed responses on its consumer panel from adults 18 to 64 in ten Midwest states, each after a consent screener, and closed the survey June 23, 2026. Questions that accepted more than one answer are shares of respondents, so they run past 100. The results reflect the panel's completed validation.